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Background: Until date, there are no clear recommendations for regular perioperative measurements of serum CEA
levels for lung cancer in any guidelines. The purpose in the present study is to evaluate the prognostic significance
of perioperative serum carcinoembryonic antigen (CEA) levels in patients with pathological-stage I non-small cell
lung cancer (NSCLC).
Methods: We retrospectively reviewed 263 completely resected pathological-stage I NSCLC patients whose
preoperative and postoperative serum CEA levels were measured. Patients were subdivided according to the
perioperative change of CEA levels: continuously normal CEA levels (NN group), continuously high CEA levels
(HH group), and high preoperative CEA levels that returned to normal levels post-operation (HN group). The
clinicopathological factors and overall survival (OS) among these 3 groups were compared. Univariate and
multivariate analyses of the correlation between clinicopathological factors and OS were performed.
Results: High preoperative CEA levels significantly correlated with men aged >70 years with smoking history, high
serum CYFRA 21–1 levels, greater tumor diameter, presence of visceral pleural invasion (VPI), and moderate-to-poor
differentiation. Five-year OS rates in the NN and HH groups were 95.5% and 59.3%, respectively. Four-year OS rate
in the HN group was 85.5%. Multivariate analyses indicated tumor diameter of more than 30 mm, presence of VPI,
and the HH group were independent unfavorable prognostic factors.
Conclusions: A high postoperative CEA level was an independent unfavorable prognostic factor in pathological-stage
I NSCLC patients. Patients with high postoperative CEA levels may benefit from adjuvant chemotherapy.
Keywords: Non-small cell lung cancer, Unfavorable prognostic factor, Pathological-stage I, Postoperative
carcinoembryonic antigen level, Adjuvant chemotherapyBackground
In many clinical practices, serum tumor markers are
easily and reproducibly evaluated. Measurement of
tumor markers in patients with malignancies enables us to
diagnose, quantitatively assess cancer cells, predict survival,
and monitor the effects of treatment.
Carcinoembryonic antigen (CEA) is one of the most
commonly used tumor markers in gastrointestinal and* Correspondence: y.kozu@scchr.jp
1Division of Thoracic Surgery, Shizuoka Cancer Center, Shimonagakubo 1007,
Nagaizumi, Shizuoka 411-8777, Japan
Full list of author information is available at the end of the article
© 2013 Kozu et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the orlung cancers. Many reports have already described the
significant correlation of preoperative CEA levels with
prognosis in patients with early-stage non-small cell lung
cancer (NSCLC) [1-7]. However, serum CEA levels are
known to be affected by the rate of CEA elimination
from circulating blood determined by renal function and
smoking status [8].
From this perspective, postoperative CEA levels might
be a more accurate prognostic factor than preoperative
CEA levels, because the former is less affected by pre-
operative smoking status. Dent et al. initially reported
high values of postoperative CEA levels [9]. Subsequentd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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levels predicted recurrence and prognosis in NSCLC
patients [4,8,10-15]. Until date, however, there are
no clear recommendations for regular perioperative
measurements of serum CEA levels for lung cancer
in any guidelines.
We conducted a retrospective study based on a single
institution to evaluate the prognostic importance of
perioperative serum CEA levels in patients with completely
resected pathological-stage I NSCLC.
Methods
Between September 2002 and December 2009, 545 patients
underwent complete surgical resection for pathological-
stage I NSCLC at the Shizuoka Cancer Center Hospital,
Shizuoka, Japan. Of these, 263 consecutive patients who
met all of the following criteria were included and retro-
spectively reviewed in the present study: (1) those who
had their serum CEA concentrations measured within
the 1-month period before surgery and again within the
2-month period after surgery (while preoperative serum
CEA levels were measured routinely, the measurement
of postoperative CEA levels was at the discretion of the
attending surgeon), (2) those without multiple lung tumors
or malignancies in other organs and (3) those who were
anticancer treatment-naïve in both the neoadjuvant setting
and adjuvant setting. Approval from the institutional ethics
committee was obtained.
The medical records of each patient were examined
for age, gender, smoking history, preoperative European
Cooperative Oncology Group performance status (ECOG
PS), both preoperative and postoperative serum CEA levels,
preoperative serum cytokeratin 19 fragment (CYFRA21-1)
levels, tumor location, surgical procedure, tumor hist-
ology, tumor diameter, visceral pleural invasion (VPI),
angiolymphatic invasion (ALI), differentiation grade,
and survival. Staging was determined according to the
seventh edition of the International Union Against Cancer
(UICC) TNM staging system [16]. Histology was evaluated
according to the latest World Health Organization’s
classification of lung tumors [17].
We performed lobectomy or pneumonectomy with sys-
temic mediastinal lymph node dissection as the standard
surgical treatment. Segmentectomy or wedge resection
was performed only on patients with tumors showing a
greater proportion of ground-glass opacity on computed
tomography or on those with major comorbidities.
Serum CYFRA21-1 concentrations were measured
within the 1-month period before surgery (at the same time
as CEA). The CEA concentration was measured using an
ARCHITECT(r) kit (Abbott Japan, Tokyo, Japan), while
the CYFRA21-1 concentration was measured using an
Lumipulse Presto(r) kit (FUJIREBIO Inc, Tokyo, Japan).
According to the manufacturer of these kits, the upperlimits of the percentiles of healthy individuals for CEA
and CYFRA21-1 levels were 5.0 ng/mL and 3.5 ng/mL,
respectively. Therefore, the cut-off point for these tumor
markers was set to the same level as the upper limits in
the present study. Patients were subdivided into 3 groups
on the basis of their shift of CEA levels by surgery as
follows: patients with continuously normal CEA levels
(NN group), patients with continuously high CEA
levels (HH group), and patients with high preoperative
CEA levels that returned to normal levels post-operation
(HN group).
ALI was defined as the presence of neoplastic cells
within an arterial, venous, or lymphatic lumen during
routine histologic evaluation with hematoxylin and eosin,
elastic van Gieson (EVG), and D2-40 stains. Because of
the retrospective nature of this study, distinction between
arterial, venous, or lymphatic invasion were not available
in some cases. Therefore, these categories were merged
into a single variable (ALI). The presence or absence of
ALI was assessed in the largest cross-sections of the
tumor in every specimen. VPI was defined as evidence of
penetration of the thick outer elastic lamina by the tumor
during EVG staining. The grade of differentiation was cat-
egorized into well differentiated, moderately differentiated,
and poorly differentiated carcinomas according to the
degree of structural and cytologic atypia. Differentiation in
squamous cell carcinoma was determined on the basis of
the degree of keratinization and the presence of intercellu-
lar bridges. Poor differentiation in squamous cell carcinoma
was defined as a tumor with faint these features and a solid
pattern. Adenocarcinoma, which is largely composed
of malignant glandular epithelium, was evaluated by
lepidic, tubular and papillary structure. Poor differenti-
ation in adenocarcinoma was defined as a solid pattern
tumor without any clear gland formation. Pathological
evaluation was performed prospectively by 2 or more
experienced pathologists.
The clinicopathological factors of the patients (n = 263)
are listed in Table 1. There were 132 men and 131
women, with a median age at surgery of 67 years
(range, 20–88 years). There were 198, 44, and 21 patients
in the NN, HN, and HH groups, respectively. Pathological
examinations revealed that there were 213 adenocarcin-
omas, 46 squamous cell carcinomas, 2 adenosquamous
carcinomas, and 2 carcinoids.
Overall survival (OS) was calculated as the period from
surgical resection until death or the date of the last
follow-up evaluation. Last actualization of survival data was
performed in September 2012. Follow-up was completed in
245 of the patients. The median time for follow-up for
surviving patients was 54 months (range, 15–120 months).
Of the total, 22 patients (8.4%) died during follow-up. The
causes of death were primary disease in 21 patients and
comorbid diseases in 1.









(n = 263) (n = 198) (n = 44) (n = 21)
Age 0.010
≤70 y 140 116 16 8
>70 y 123 82 28 13
Gender 0.002
Male 132 87 30 15
Female 131 111 14 6
Smoking history < 0.001
≥5 PY 135 85 33 17
<5 PY 128 113 11 4
ECOG PS 0.28
0 222 169 38 15
1 41 29 6 6
Serum CYFRA 0.039
>3.5 ng/mL 12 5 5 2
≤3.5 ng/mL 251 193 39 19
Location 0.77
Right 167 124 30 13
Left 96 74 14 8
Surgical procedure 0.98
Sublobar resection 38 29 6 3
Major resection b 225 169 38 18
Tumor diameter 0.002
>30 mm 53 30 17 6
≤30 mm 210 168 27 15
Histology 0.27
Adeno 213 165 33 15
Squamous 46 30 11 5
Others 4 3 0 1
VPI 0.037
Present 50 31 11 8
Absent 213 167 33 13
ALI 0.32
Present 66 49 9 8
Absent 197 149 35 13
Differentiation c < 0.001
Well 168 140 19 9
Moderate/Poor 91 55 25 11
PY, Pack-years; ECOG PS, European cooperative oncology group performance
status; CYFRA, Cytokeratin 19 fragment; VPI, Visceral pleural invasion; ALI,
Angiolymphatic invasion.
aassociation between the NN group and HN group, the chi-square test.
b Major resection refers to lobectomy or pneumonectomy.
c The grade of differentiation was not determined in 4 patients with
adenosquamous carcinoma or carcinoids.
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Counts were compared using the chi-square test. The
Kaplan-Meier method was used to generate survival
curves, and survival differences were analyzed using the
log-rank test. Multivariate analyses of prognostic factors
were performed using the Cox proportional hazards model.
A p- value of less than 5% was considered significant. All
statistical analyses were performed using JMP 9 software
(SAS Institute, Cary, NC, USA).
Results
Patients’ clinicopathological factors according to the CEA
group
The HN group significantly correlated to older men (>70 y)
with a smoking history (≥5 pack-years), high serum
CYFRA 21–1 levels (>3.5 ng/mL), greater tumor diameter
(>30 mm), presence of VPI, and moderate-to-poor differen-
tiation compared to the NN group (Table 1).
OS curves according to the CEA group
Five-year OS rates in the NN and HH groups were
95.5% and 59.3%, respectively. Four-year OS rate in the
HN group was 85.5%. A significant difference in OS was
observed between the HN and NN groups (p = 0.043).
A trend toward a decreased survival was observed for
the HH group compared to the HN group, but was not
statistically significant (p = 0.062). These survival curves
are shown in Figure 1.
Predictors of OS according to univariate analyses
The results of univariate analyses for survival are
summarized in Table 2. The clinicopathological factors of
age, ECOG PS, serum CEA levels, tumor diameter, VPI,
ALI, and differentiation grade were significant prognostic
factors for OS.
Predictors of OS according to multivariate analyses
Multivariate analyses for OS were performed using
these factors, and the results are summarized in Table 3.
Tumor diameter of more than 30 mm (hazard ratio
[HR] = 3.47, 95% confidence interval [CI]: 1.35–8.98,
p = 0.010), presence of VPI (HR = 3.18, 95% CI: 1.11–
8.84, p = 0.032), and the HH group (HR = 7.69, 95% CI:
2.46–23.7, p < 0.001) were found to be independent
unfavorable prognostic factors.
OS curves according to the number of unfavorable
prognostic factors
Figure 2 shows OS curves according to the number of
independent unfavorable prognostic factors (tumor diameter
of more than 30 mm, presence of VPI, and the HH group)
on the basis of the results of multivariate analyses.
Five-year OS rate was 58.0% for those harboring 2 or
more unfavorable prognostic factors (n = 25).
Red line: NN group
Green line: HN group
Blue line: HH group
p = 0.043
p = 0.062
Figure 1 Overall survival curves according to the CEA group. A
significant difference in overall survival was observed between the
HN group and NN group (p = 0.043). There was a marginally
significant difference in overall survival between the HH group and
HN group (p = 0.062). CEA, carcinoembryonic antigen.
Table 3 Predictors of OS according to multivariate analysis
Risk factors HR 95% CI p value a
Age
≤70 y 1 Reference
>70 y 2.29 0.87–6.72 0.095
ECOG PS
0 1 Reference
1 1.33 0.47–3.53 0.59
Tumor diameter
≤30 mm 1 Reference
>30 mm 3.47 1.35–8.98 0.010
VPI
Absent 1 Reference
Present 3.18 1.11–8.84 0.032
ALI
Absent 1 Reference
Present 1.06 0.38–3.15 0.91
Differentiation
Well 1 Reference
Moderate/Poor 1.14 0.42–3.01 0.80
Serum CEA
NN group 1 Reference
HN group 2.52 0.72–8.11 0.14
HH group 7.69 2.46–23.7 < 0.001
OS, Overall survival; HR, Hazard ratio; CI, Confidence interval; ECOG PS,
European cooperative oncology group performance status; VPI, Visceral pleural
invasion; ALI, Angiolymphatic invasion; CEA, Carcinoembryonic antigen.
a the log-rank test.
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There have been 3 reports published, which were similar
in design to the present study [4,11,15] and subdivided
pathological-stage I NSCLC patients into 3 groups, viz.
the NN, HN, and HH groups (Table 4). These previous
reports have demonstrated that the worst prognosis
correlates to the HH group, consistent with results of
the present study. Taken together, these results suggest
that failure to normalize CEA levels after surgery is
associated with a significantly worse prognosis. Okada et al.
speculated that failure to achieve normal levels of CEA
levels is caused either by unrecognized extrapulmonaryTable 2 Predictors of OS according to univariate analysis
Risk factors Favorable Unfavorable p Value a
Age ≤70 y >70 y 0.008
Gender Female Male 0.12
Smoking history <5 PY ≥5 PY 0.088
ECOG PS 0 1 0.007
Serum CEA NN group HN group 0.043
HN group HH group 0.062
Serum CYFRA ≤3.5 ng/mL >3.5 ng/mL 0.90
Location Left Right 0.99
Surgical procedure Major resection b Sublobar resection 0.57
Tumor diameter ≤30 mm >30 mm < 0.001
Histology Adeno Others 0.070
VPI Absent Present 0.001
ALI Absent Present 0.008
Differentiation Well Moderate/Poor 0.037
OS, Overall survival; PY, Pack-years; ECOG PS, European cooperative oncology
group performance status; CEA, Carcinoembryonic antigen; CYFRA, Cytokeratin
19 fragment level; VPI, Visceral pleural invasion; ALI, Angiolymphatic invasion.
a the log-rank test.
b Major resection refers to lobectomy or pneumonectomy.
Unfavorable 
prognostic factor
Red line 0 
Green line 1 
Blue line 2-3
Figure 2 Overall survival curves according to the number of
independent unfavorable prognostic factors (tumor diameter
of more than 30 mm, presence of VPI, and the HH group) on
the basis of the results of multivariate analyses. Five-year overall
survival rate was 58.0% for those harboring 2 or more unfavorable
prognostic factors (n = 25). VPI, visceral pleural invasion.
Table 4 Comparison of the previous reports analyzing the perioperative change of serum CEA levels in patients with
pathological stage-I NSCLC
Author Okada [4] Matsuguma [11] Wang [15] Present study
Year 2004 2008 2010 2013
CEA measurement period Before surgery Within 1 M Within 1 M Within 2 W Within 1 M
After surgery Within 1 M Within 1–3 M Within 1–3 M Within 2 M
Cut-off point (ng/mL) 5.0 5.0 6.0 5.0
Total number 722 a 455 257 263
NN group (5-ys) 472 (84.2%) 323 (85.9%) 173 (71.1%) 198 (95.5%)
HN group 154 (74.2%) 112 (56.2%) 56 (54.6%) 44 (85.5%) b
HH group 96 (48.6%) 20 (43.1%) 28 (36.0%) 21 (59.3%)
Independent prognostic factor N/A Age Age Tumor diameter
Histology HH group VPI
VPI HH group
HN/HH group
CEA, Carcinoembryonal antigen; NSCLC, Non-small cell lung cancer; M, Month; W, Week; N/A, Not analyzed; VPI, Visceral pleural invasion.
a including incomplete resections.
b 4-ys.
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The results in the current study show that the 5-year OS
rate in the HH group was 59.3%, the highest compared
to those in previous reports (range, 36.0%–48.6%). A
similar trend was observed among the HN and NN groups
as well. The previous reports included incomplete resec-
tions [4] and higher percentages of pathological-stage IB
patients (60.3% vs. 33.0% compared with the present study)
[15], and these differences could be the possible reason for
decreased survival.
Matsuguma et al. reported that preoperative high CEA
levels significantly correlated with smoking-related factors
such as increased age, male gender, squamous cell carcin-
oma, pathological T2 status, vascular invasion, VPI, and
moderate-to-poor differentiation (only in adenocarcinomas)
[11]. These observations are mostly consistent with those
reported in the present study. Wang et al. reported that
histologic adenocarcinomas significantly correlated with
high preoperative CEA levels, whereas age, smoking status,
tumor diameter, VPI, and pathological-stage did not [15].
One of the most notable differences between the current
study and previous reports is that we did not observe
any significant correlation between CEA levels and
histologic type. Although CEA was initially investigated
in colon adenocarcinoma, it has been known to be
elevated in patients with squamous cell carcinoma of
the lung, uterine cervix, and esophagus [18-22]. The
correlation of CEA levels and histologic subtype of
NSCLC remained still controversial.
Our results indicate that tumor diameter of more
than 30 mm, presence of VPI, and the HH group were
independent unfavorable prognostic factors. The former 2
factors are the most representative determinants for lung
cancers to be categorized as T2a according to the seventhedition of the UICC TNM staging system [16]. Since
T2aN0M0 lung cancers are staged as pathological-
stage IB, our results confirmed the prognostic value of
pathological-stage classification, which is the most
widely-used prognosticator in lung cancer.
We also highlighted the prognostic significance of
continuously high perioperative CEA levels (HH group),
consistent with the results by Wang et al. [15]. Because
all of the patients with postoperative high CEA levels
had preoperative high CEA levels as well, the results
indicate the need for measuring postoperative CEA
levels rather than preoperative CEA levels. On the other
hand, Matsuguma et al. reported that both HN and HH
groups were independent unfavorable prognostic factors
[11], indicating the need for measuring preoperative
CEA levels. In the Western countries, however, regular
perioperative measurement of serum CEA levels in
patients with lung cancer is not commonly performed
and is considered less convincing than in patients
with colorectal cancer [4,23].
In Japan, adjuvant chemotherapy with UFT is
recommended in pathological-stage IB NSCLC patients
because the occurrence of postoperative death was found
to have decreased in the UFT group as compared to the
control group in previous studies [24,25]. As mentioned
earlier, our results indicate the prognostic significance of
discriminating pathological-stage IB from IA, supporting
this recommendation. The most important clinical
implications emerging from this study is that patients
with postoperative high CEA levels are also good
candidates for adjuvant chemotherapy in addition to
pathological-stage IB patients. Although in-anatomical
factors of tumor markers are not reflected in the current
TNM staging system, the results of our study indicate
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representing micrometastases or residual tumor cells,
which may not be detected by radiological images and
pathological examination.
Independent prognostic significance of postoperative
high CEA levels is yet to be proved in advanced NSCLC
patients. Sawabata et al. speculated that this might be
attributable to the stronger prognostic impact of anatomic
factors such as lymph node metastases than tumor
markers [13]. On the other hand, Fukai et al. reported that
an elevated preoperative CEA levels (≥5 ng/mL) was an
independent predictor of survival even in pT1-2N1M0
NSCLC patients [26]. These studies therefore suggest that
the prognostic significance of high postoperative CEA levels
should also be validated in advanced NSCLC patients.
The present study has several limitations: First is its
retrospective nature; second, postoperative CEA levels
were measured at the discretion of the attending surgeon,
adding significant selective bias into the present study;
third, there was a small sample size of the HH group
(n = 21) and observed events, making it statistically difficult
to interpret results.
Conclusions
A high postoperative CEA level was an independent
unfavorable prognostic factor in completely resected
pathological-stage I NSCLC patients. Those with post-
operative high CEA levels may benefit from adjuvant
chemotherapy.
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